Afynia Laboratories Closes $5M Seed Round, Proceeds to Help Revolutionize Endometriosis Care

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Afynia Laboratories, a biotechnology company specializing in innovative solutions for women’s health, recently announced the closing of a $5 million funding round. The investment was led by Bio-Rad Laboratories, with participation from Impact America Fund, SOSV, the Capital Angel Network, and Gaingels. The funding will be used to progress Afynia’s pipeline of women’s health diagnostics initially focused on endometriosis.

Afynia Laboratories is an alumnus of our WiHI program and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Stem Cell Network and Capital BioVentures Announce a Strategic Partnership to Drive Canadian Regenerative Innovations Forward
Next

OBIO® and TIAP Invest in A4i to Advance AI Analytics for Mental Health Risk Detection